logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11090326 B1

PDFFull Text
Date of Patent:
Aug. 17, 2021

Filed:

Mar. 12, 2020

Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine

Applicant:

Redhill Biopharma Ltd., Tel-Aviv, IL;

Inventors:

Thomas Julius Borody, Five Dock, AU;

Patrick Gosselin, Laval, CA;

Assignee:

RedHill Biopharma Ltd., Tel-Aviv, IL;

Attorney:

Greenberg Traurig, LLP

Primary Examiner:

Savitha M Rao

Int. Cl.
CPC ...
A61K 31/7048 (2006.01); A61K 31/395 (2006.01); A61K 31/498 (2006.01); A61K 31/44 (2006.01); A61K 31/438 (2006.01); A61K 31/435 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 9/48 (2006.01); A61P 43/00 (2006.01); A61P 31/04 (2006.01); A61P 31/00 (2006.01); A61P 29/00 (2006.01); A61P 1/04 (2006.01); A61P 1/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/395 (2013.01); A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/44 (2013.01); A61K 31/498 (2013.01); A61K 47/10 (2013.01); A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 31/04 (2018.01); A61P 43/00 (2018.01);
Abstract

Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to,subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.

Find Patent Forward Citations

Loading…